The effectiveness of antibacterial therapeutic clothing based on silver or chitosan as compared with non-antibacterial therapeutic clothing in patients with moderate to severe atopic dermatitis (ABC trial): study protocol for a pragmatic randomized controlled trial

Aviël Ragamin, Karin B Fieten, Ron A Tupker, Jill de Wit, Minke M F van Mierlo, Marieke S Jansen, Madelon B Bronner, Renske Schappin, Frank H J Schuren, Margreet L E Romeijn, Bernd W M Arents, Suzanne Polinder, Marlies de Graaf, Thomas Rustemeyer, Marie L A Schuttelaar, Suzanne G M A Pasmans, Aviël Ragamin, Karin B Fieten, Ron A Tupker, Jill de Wit, Minke M F van Mierlo, Marieke S Jansen, Madelon B Bronner, Renske Schappin, Frank H J Schuren, Margreet L E Romeijn, Bernd W M Arents, Suzanne Polinder, Marlies de Graaf, Thomas Rustemeyer, Marie L A Schuttelaar, Suzanne G M A Pasmans

Abstract

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects 10 to 20% of children and between 2 and 15% of the adults in Western Europe. Since 2000, therapeutic clothing or functional textiles based on silver or chitosan as antibacterial agents were introduced for AD. These agents aim to reduce skin colonization with Staphylococcus (S.) aureus. Increased colonization with S. aureus is correlated with increased AD severity. The antimicrobial effects of silver and chitosan have been demonstrated before. At this point, there is insufficient evidence for the effectiveness of antibacterial therapeutic clothing in patients with AD.

Methods: This is a pragmatic randomized controlled double-blind multi-center trial comparing the effectiveness of antibacterial therapeutic clothing based on silver or chitosan as compared with non-antibacterial therapeutic clothing in patients with moderate to severe AD. A total of 165 participants, aged 0 to 80, diagnosed with moderate to severe AD are included. The study is performed in the Erasmus MC University Medical Center, University Medical Center Groningen, University Medical Center Utrecht, Amsterdam University Medical Centers, and St. Antonius Hospital Nieuwegein. Patients will be randomized 1:1:1 into one of the three intervention groups: group A will receive therapeutic clothing without antimicrobial agents, group B will receive microbial growth reducing therapeutic clothing based on chitosan, and group C will receive antimicrobial clothing based on silver. All therapeutic clothing is to be worn at night during the 12-month intervention period. Usual care is continued. The primary objective is to assess the effectiveness of antibacterial clothing (silver and chitosan group) as compared to non-antibacterial clothing assessed with the Eczema Area and Severity Index at 12 months compared to baseline. Secondary outcomes include between-group differences in physician- and patient-reported outcome measures, topical therapy use, S. aureus skin colonization, and safety. Data will be collected at baseline and after 1 month, 3 months, 6 months, and 12 months. A cost-effectiveness analysis will be performed.

Discussion: This trial will provide data on the effectiveness, cost-effectiveness, and safety of antibacterial therapeutic clothing for patients with AD.

Trial registration: ClinicalTrials.gov NCT04297215. Registered on 5 March 2020.

Keywords: Antibacterial; Atopic dermatitis; Randomized controlled trial; Therapeutic clothing; Topical corticosteroids; Treatment.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Flowchart of the study design
Fig. 2
Fig. 2
SPIRIT diagram of study procedures. *Optional

References

    1. Odhiambo JA, Williams HC, Clayton TO. Robertson CF, Asher MI, Group IPTS Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124(6):1251–1258. doi: 10.1016/j.jaci.2009.10.009.
    1. Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22(2):125–137. doi: 10.5021/ad.2010.22.2.125.
    1. Willemsen MG, van Valburg RW, Dirven-Meijer PC, Oranje AP, van der Wouden JC, Moed H. Determining the severity of atopic dermatitis in children presenting in general practice: an easy and fast method. Dermatol Res Pract. 2009;2009:357046. doi: 10.1155/2009/357046.
    1. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, Gieler U, Lipozencic J, Luger T, Oranje AP, Schäfer T, Schwennesen T, Seidenari S, Simon D, Ständer S, Stingl G, Szalai S, Szepietowski JC, Taïeb A, Werfel T, Wollenberg A, Darsow U. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045–1060. doi: 10.1111/j.1468-3083.2012.04635.x.
    1. Lansdown AB. Silver in health care: antimicrobial effects and safety in use. Curr Probl Dermatol. 2006;33:17–34. doi: 10.1159/000093928.
    1. Zhang Z, Chen L, Ji J, Huang Y, Chen D. Antibacterial properties of cotton fabrics treated with chitosan. Text Res J. 2003;73(12):1103–1106. doi: 10.1177/004051750307301213.
    1. Zollner TM, Wichelhaus TA, Hartung A, Von Mallinckrodt C, Wagner TO. Brade V, et al. Colonization with superantigen-producing Staphylococcus aureus is associated with increased severity of atopic dermatitis. Clin Exp Allergy. 2000;30(7):994–1000. doi: 10.1046/j.1365-2222.2000.00848.x.
    1. Totte JE, van der Feltz WT, Hennekam M, van Belkum A, van Zuuren EJ, Pasmans SG. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016;175(4):687–695. doi: 10.1111/bjd.14566.
    1. NVDV . Clinical guideline of the Dutch Society for Dermatology and Venerology: therapeutic clothing for atopic dermatitis, addendum to the CBO guideline atopic dermatitis. 2007. Rapport Verbandmiddelen bij constitutioneel eczeem. Addendum van de CBO-richtlijn Constitutioneel Eczeem 2007.
    1. NVDV . Clinical guideline of the Dutch Society for Dermatology and Venerology: guideline atopic dermatitis. 2019. Richtlijn Constitutioneel eczeem 2019.
    1. C.B.M. Nyst HHCdV, J. Heymans, H.M. Gaasbeek Janzen. Antibacterië le verbandkleding bij constitutioneel eczeem. 2015. Dutch National Health Care Institute: Antibacterial therapeutic clothing for atopic dermatits. Available from: . Accessed 28 November 2021.
    1. Araujo CP, Gomes J, Vieira AP, Ventura F, Fernandes JC, Brito C. A proposal for the use of new silver-seaweed-cotton fibers in the treatment of atopic dermatitis. Cutan Ocul Toxicol. 2013;32(4):268–274. doi: 10.3109/15569527.2013.775655.
    1. Lopes C, Silva D, Delgado L, Correia O, Moreira A. Functional textiles for atopic dermatitis: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2013;24(6):603–613. doi: 10.1111/pai.12111.
    1. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working party’s diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol. 1994;131(3):406–416. doi: 10.1111/j.1365-2133.1994.tb08532.x.
    1. Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, Kantor R, Hsu DY, Silverberg JI. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316–1321. doi: 10.1111/bjd.15641.
    1. Thomas KS, Bradshaw LE, Sach TH, Batchelor JM, Lawton S, Harrison EF, Haines RH, Ahmed A, Williams HC, Dean T, Burrows NP, Pollock I, Llewellyn J, Crang C, Grundy JD, Guiness J, Gribbin A, Mitchell EJ, Cowdell F, Brown SJ, Montgomery AA, UK Dermatology Clinical Trials Network’s CLOTHES Trial Team Silk garments plus standard care compared with standard care for treating eczema in children: a randomised, controlled, observer-blind, pragmatic trial (CLOTHES Trial) PLoS Med. 2017;14(4):e1002280. doi: 10.1371/journal.pmed.1002280.
    1. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106. doi: 10.1111/j.1398-9995.2011.02719.x.
    1. ALEA. Tools for Clinical Trials. 2018. Available from: . Accessed 28 Nov 2020.
    1. Pluut OA, Bianco C, Jakasa I, Visser MJ, Krystek P, Larese-Filon F, Rustemeyer T, Kezic S. Percutaneous penetration of silver from a silver containing garment in healthy volunteers and patients with atopic dermatitis. Toxicol Lett. 2015;235(2):116–122. doi: 10.1016/j.toxlet.2015.03.014.
    1. Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI, Beck LA, Bieber T, Reich K, Kabashima K, Seyger M, Siegfried E, Stingl G, Feldman SR, Menter A, van de Kerkhof P, Yosipovitch G, Paul C, Martel P, Dubost-Brama A, Armstrong J, Chavda R, Frey S, Joubert Y, Milutinovic M, Parneix A, Teixeira HD, Lin CY, Sun L, Klekotka P, Nickoloff B, Dutronc Y, Mallbris L, Janes JM, DeLozier AM, Nunes FP, Paller AS. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839–846. doi: 10.1016/j.jaad.2020.04.104.
    1. Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S, Dohil M, Apfelbacher C, Singh JA, Chalmers J, Williams HC. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134(4):800–807. doi: 10.1016/j.jaci.2014.07.043.
    1. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513–1519. doi: 10.1001/archderm.140.12.1513.
    1. Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbé A, Nelson L, Clark M, Williams N, Chen Z, Ardeleanu M, Akinlade B, Graham NMH, Pirozzi G, Staudinger H, Plaum S, Radin A, Gadkari A. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–769. doi: 10.1111/bjd.17744.
    1. Howells LM, Chalmers JR, Gran S, Ahmed A, Apfelbacher C, Burton T, Howie L, Lawton S, Ridd MJ, Rogers NK, Sears AV, Spuls P, Kobyletzki L, Thomas KS. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: recap of atopic eczema (RECAP) Br J Dermatol. 2020;183(3):524–536. doi: 10.1111/bjd.18780.
    1. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x.
    1. Fekkes M, Theunissen NC, Brugman E, Veen S, Verrips EG, Koopman HM, et al. Development and psychometric evaluation of the TAPQOL: a health-related quality of life instrument for 1-5-year-old children. Qual Life Res. 2000;9(8):961–972. doi: 10.1023/A:1008981603178.
    1. Kreimeier S, Greiner W. EQ-5D-Y as a health-related quality of life instrument for children and adolescents: the instrument’s characteristics, development, current use, and challenges of developing its value set. Value Health. 2019;22(1):31–37. doi: 10.1016/j.jval.2018.11.001.
    1. Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br J Dermatol. 1998;138(1):107–113. doi: 10.1046/j.1365-2133.1998.02034.x.
    1. Basra MK, Edmunds O, Salek MS, Finlay AY. Measurement of family impact of skin disease: further validation of the Family Dermatology Life Quality Index (FDLQI) J Eur Acad Dermatol Venereol. 2008;22(7):813–821. doi: 10.1111/j.1468-3083.2008.02593.x.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit